Consensus Repligen Corporation

Equities

RGEN

US7599161095

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
166.6 ^USD	+0.56%		+6.01%	-7.35%

04-08	RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating	MT
03-20	Transcript : Repligen Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 03:00 PM

Evolution of the average Target Price on Repligen Corporation

Price target over the last 5 years

History of analyst recommendation changes

d98d9b48b0a6.K5ypDIoeWPmCqE13M8xL3qa-jDZaBF_djB6xoJqtcoI.W6XgPOQoKrfT5SAYAroAteiH_VgVTjSb9SiI5fuYIPJfq5lly0YWqO_feQ~5e39be2261dcaf30274b0ef2efab00ce

Analyst Recommendations on Repligen Corporation

RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating	04-08	MT
UBS Adjusts Repligen Price Target to $225 From $211, Maintains Buy Rating	02-22	MT
Deutsche Bank Adjusts Repligen Price Target to $180 From $175, Maintains Hold Rating	02-22	MT
RBC Raises Price Target on Repligen to $225 From $200, Keeps Outperform Rating	02-22	MT
Stocks Decline Pre-Bell as Fed Outlook, Rates Weigh; Asia Mixed, Europe Mostly Up	02-21	MT
Deutsche Bank Adjusts Repligen Price Target to $175 From $150, Maintains Hold Rating	12-18	MT
UBS Adjusts Repligen Price Target to $211 From $170, Maintains Buy Rating	12-15	MT
Benchmark Downgrades Repligen to Hold From Buy	12-04	MT
Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating	11-07	MT
CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating	11-03	MT
RBC Trims Price Target on Repligen to $837 From $847, Keeps Sector Perform Rating	11-03	MT
UBS Adjusts Repligen Price Target to $170 From $210, Maintains Buy Rating	11-01	MT
KeyBanc Lowers Price Target on Repligen to $210 From $240, Maintains Overweight Rating	11-01	MT
Craig Hallum Cuts Repligen Price Target to $175 From $200, Maintains Buy Rating	11-01	MT
RBC Cuts Price Target on Repligen to $200 From $207, Keeps Outperform Rating	11-01	MT
JPMorgan Cuts Repligen Price Target to $180 From $200, Maintains Overweight Rating	23-10-17	MT
UBS Adjusts Repligen Price Target to $210 From $199, Maintains Buy Rating	23-08-03	MT
Stephens Adjusts Price Target on Repligen to $200 From $180, Maintains Overweight Rating	23-08-03	MT
RBC Boosts Price Target on Repligen to $195 From $157, Keeps Outperform Rating	23-08-03	MT
Wells Fargo Initiates Coverage on Repligen With Overweight Rating, $185 Price Target	23-07-20	MT
RBC Upgrades Repligen to Outperform From Sector Perform, Price Target is $157	23-07-06	MT
UBS Adjusts Repligen Price Target to $199 From $210, Maintains Buy Rating	23-05-15	MT
Powell's mixed signals and Pacwest weigh on US indices	23-05-04
ANALYST RECOMMENDATIONS : AMD, Avis, Clorox, Flutter, Starbucks...	23-05-04
Deutsche Bank Adjusts Repligen Price Target to $165 From $180, Maintains Hold Rating	23-05-03	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

166.6 USD

Average target price

210.9 USD

Spread / Average Target

+26.59%

High Price Target

230 USD

Spread / Highest target

+38.07%

Low Price Target

180 USD

Spread / Lowest Target

+8.06%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Repligen Corporation

RBC Capital Markets
UBS
Deutsche Bank Securities
Benchmark Company
KeyBanc Capital Markets
Craig-Hallum
JPMorgan Chase
Stephens Inc.
Wells Fargo Securities
Stifel Nicolaus
SVB Securities LLC
SVB Leerink
Exane BNP Paribas
William O'Neil & Co
HC Wainwright

Ratings for Repligen Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar